BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2:8-16. [PMID: 15968334 DOI: 10.7150/ijms.2.8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 França P, Coelho H, Brandão C, Segadas J, Quintaes R, Carrilho F, Ono-nita S, Mattos A, Tovo C, Gouvea V, Sablon E, Vanderborght B. The emergence of YMDD mutants precedes biochemical flare by 19 weeks in lamivudine-treated chronic hepatitis B patients: an opportunity for therapy reevaluation. Braz J Med Biol Res 2007;40:1605-14. [DOI: 10.1590/s0100-879x2006005000169] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Sayed SK, Kobeisy MA. The relationship between core promoter mutation of hepatitis B virus, viral load and hepatitis B e antigen status in chronic hepatitis B patients. Cell Immunol. 2012;276:35-41. [PMID: 22551558 DOI: 10.1016/j.cellimm.2012.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
3 Joshi H, Lewis K, Singharoy A, Ortoleva PJ. Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design. Vaccine 2013;31:4841-7. [PMID: 23933338 DOI: 10.1016/j.vaccine.2013.07.075] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
4 Calin R, Guiguet M, Desire N, Imbert-Bismut F, Munteanu M, Poynard T, Valantin MA, Stitou H, Katlama C, Thibault V. Role of genotype G hepatitis B virus mixed infection on the progression of hepatic fibrosis in HIV positive patients over 5 years of follow-up. J Clin Virol. 2013;58:408-414. [PMID: 23958588 DOI: 10.1016/j.jcv.2013.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
5 Morgnanesi D, Heinrichs EJ, Mele AR, Wilkinson S, Zhou S, Kulp JL 3rd. A computational chemistry perspective on the current status and future direction of hepatitis B antiviral drug discovery. Antiviral Res 2015;123:204-15. [PMID: 26477294 DOI: 10.1016/j.antiviral.2015.10.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
6 Fathi MS, El-folly RF, Hassan RA, El-arab ME. Genotypic and phenotypic patterns of antimicrobial susceptibility of Helicobacter pylori strains among Egyptian patients. Egyptian Journal of Medical Human Genetics 2013;14:235-46. [DOI: 10.1016/j.ejmhg.2013.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
7 Duarte G, Pezzuto P, Barros TD, Mosimann Junior G, Martínez-Espinosa FE. [Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis]. Epidemiol Serv Saude 2021;30:e2020834. [PMID: 33729415 DOI: 10.1590/S1679-4974202100016.esp1] [Reference Citation Analysis]
8 Zhang M, Ge G, Yang Y, Cai X, Fu Q, Cai J, Huang Z. Decreased antigenicity profiles of immune-escaped and drug-resistant hepatitis B surface antigen (HBsAg) double mutants. Virol J 2013;10:292. [PMID: 24053482 DOI: 10.1186/1743-422X-10-292] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
9 Solmone M, Vincenti D, Prosperi MC, Bruselles A, Ippolito G, Capobianchi MR. Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen. J Virol. 2009;83:1718-1726. [PMID: 19073746 DOI: 10.1128/jvi.02011-08] [Cited by in Crossref: 126] [Cited by in F6Publishing: 79] [Article Influence: 9.7] [Reference Citation Analysis]
10 Shi M, Yang ZJ, Wang RS, Zhang H, Zhu YF, Xu YP, Lin QY, Jin LJ. Rapid quantitation of lamivudine-resistant mutants in lamivudine treated and untreated patients with chronic hepatitis B virus infection. Clin Chim Acta. 2006;373:172-175. [PMID: 16814763 DOI: 10.1016/j.cca.2006.05.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
11 Poordad F, Chee GM. Viral resistance in hepatitis B: prevalence and management. Curr Gastroenterol Rep 2010;12:62-9. [PMID: 20425486 DOI: 10.1007/s11894-009-0088-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
12 Cui J, Kang X, Dai Z, Huang C, Zhou H, Guo K, Li Y, Zhang Y, Sun R, Chen J, Li Y, Tang Z, Uemura T, Liu Y. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J Cancer Res Clin Oncol 2007;133:825-34. [PMID: 17516088 DOI: 10.1007/s00432-007-0224-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
13 Duarte G, Pezzuto P, Barros TD, Mosimann Junior G, Martinez-Espinosa FE. Brazilian Protocol for Sexually Transmitted Infections 2020: viral hepatitis. Rev Soc Bras Med Trop 2021;54:e2020834. [PMID: 34008732 DOI: 10.1590/0037-8682-834-2020] [Reference Citation Analysis]
14 Seto WK, Lai CL, Fung J, Wong DK, Yuen JC, Hung IF, Yuen MF. Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. J Hepatol. 2011;55:522-528. [PMID: 21147187 DOI: 10.1016/j.jhep.2010.11.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lau DT, Bleibel W. Current status of antiviral therapy for hepatitis B. Therap Adv Gastroenterol. 2008;1:61-75. [PMID: 21180515 DOI: 10.1177/1756283x08093944] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Baxa DM, Thekdi AD, Golembieski A, Krishnan PV, Sharif O, Kizy A, Shetron-Rama L, Jovanovich J, Chappell BJ, Snow-Lampart A. Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States. J Hepatol. 2013;58:212-216. [PMID: 23022497 DOI: 10.1016/j.jhep.2012.09.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
17 Kim JK, Lee HJ, Lee YJ, Chun JY, Lee IK, Lim YS, Suh DJ, Ko SY, Kim MH, Oh HB. Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers. J Virol Methods. 2008;149:76-84. [PMID: 18291537 DOI: 10.1016/j.jviromet.2008.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
18 Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine. 2000;18 Suppl 1:S17-S19. [PMID: 10683537 DOI: 10.1186/1743-422x-4-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
19 Makhlouf NA, Morsy KH, Othman ER, Eldin EN. Ante-natal screening of pregnant women for hepatitis B virus infection in Upper Egypt: A Tertiary Care Center Based Study. Egyptian Liver Journal 2014;4:57-62. [DOI: 10.1097/01.elx.0000445723.55972.3a] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol. 2006;44:593-606. [PMID: 16455151 DOI: 10.1016/j.jhep.2006.01.001] [Cited by in Crossref: 148] [Cited by in F6Publishing: 143] [Article Influence: 9.9] [Reference Citation Analysis]
21 Wang XL, Xie SG, Zhang L, Yang WX, Wang X, Jin HZ. Comparison of ligase detection reaction and real-time PCR for detection of low abundant YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2008; 14(1): 120-124 [PMID: 18176973 DOI: 10.3748/wjg.14.120] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ahmed CS, Wang ZH, Bin Z, Chen JJ, Kamal M, Hou JL. Hepatitis B virus genotypes, subgenotypes, precore, and basal core promoter mutations in the two largest provinces of Pakistan. J Gastroenterol Hepatol 2009;24:569-73. [PMID: 19368634 DOI: 10.1111/j.1440-1746.2008.05642.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
23 Yang ZJ, Tu MZ, Liu J, Wang XL, Jin HZ. Comparison of amplicon-sequencing, pyrosequencing and real-time PCR for detection of YMDD mutants in patients with chronic hepatitis B. World J Gastroenterol 2006; 12(44): 7192-7196 [PMID: 17131486 DOI: 10.3748/wjg.v12.i44.7192] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
24 Seto WK, Yuen MF, Fung J, Lai CL. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 2013;7:327-34. [PMID: 21688182 DOI: 10.1007/s12072-011-9282-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 Hosseini SY, Sabahi F, Amini-Bavil-Olyaee S, Alavian SM, Merat S. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains. J Virol Methods 2006;137:298-303. [PMID: 16962669 DOI: 10.1016/j.jviromet.2006.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
26 Niesters HG, Zoulim F, Pichoud C, Buti M, Shapiro F, D'Heuvaert N, Celis L, Doutreloigne J, Sablon E. Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment. Antimicrob Agents Chemother 2010;54:1283-9. [PMID: 20065049 DOI: 10.1128/AAC.00970-09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
27 Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44:1060-1071. [PMID: 22531713 DOI: 10.1016/j.biocel.2012.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
28 Zaky S, Farghaly AM, Rashed H, Hassan H, Faouzy E, Makhlouf N, Hussein MRA. Clinicopathologic features and genotyping of patients with chronic HBV infection in the Upper Egypt. Cellular Immunology 2010;265:97-104. [DOI: 10.1016/j.cellimm.2010.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]